Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1)

Secondo Lastoria, Francesca Marciello, Antongiulio Faggiano, Luigi Aloj, Corradina Caracò, Michela Aurilio, Laura D’Ambrosio, Francesca Di Gennaro, Valeria Ramundo, Luigi Camera, Leonardo de Luca, Rosa Fonti, Vincenzo Napolitano, Annamaria Colao

Research output: Contribution to journalArticle

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is a hereditary syndrome predisposing to many endocrine and neuroendocrine tumors (NET). Conventional imaging (CI) cannot provide satisfactory results for all the different types of MEN1-related tumors. Objective of this prospective observational study was to evaluate the role of 68Ga-DOTATATE PET/CT in MEN1 compared to CI. Diagnostic performance of 68Ga-DOTATATE PET/CT for the detection of NET was evaluated as well as the prognostic role of SUVmax. Eighteen patients with genetically confirmed MEN1 were evaluated by 68Ga-DOTATATE PET/CT, endoscopic ultrasounds, multidetector-row computed tomography, magnetic resonance imaging, and hormone/markers serum measurements. Four MEN1-related tumor sites (pancreas, pituitary, parathyroids, adrenals) were considered. Sensitivity and specificity of 68Ga-DOTATATE PET/CT for the detection of NET were calculated. There was 68Ga-DOTATATE PET/CT uptake in 11/11 patients with pancreatic lesions, in 9/12 with pituitary adenoma, in 5/15 with parathyroid enlargements, and in 5/7 with adrenal lesions. 68Ga-DOTATATE PET/CT showed sensitivity and specificity of 100 and 100 % in pancreas, 75 and 83 % in pituitary, 28 and 100 % in parathyroids, and 62.5 and 100 % in adrenals, respectively. Compared with CI, no significant difference in sensitivity for pancreas, pituitary, and adrenals was found, while CI had a better sensitivity for parathyroids (p = 0.002). On the ROC analysis, progression of pancreatic lesions was significantly associated to SUVmax 68Ga-DOTATATE PET/CT is greatly helpful in the work-up of MEN1 providing a panoramic view of MEN1-related lesions. There is also a prognostic role of 68Ga-PET in patients with MEN1-pancreatic lesions.

Original languageEnglish
JournalEndocrine
DOIs
Publication statusPublished - 2016

Keywords

  • <sup>68</sup>Ga-DOTATATE PET/CT
  • Hyperparathyroidism
  • MEN1
  • Neuroendocrine tumor
  • Pituitary adenoma

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Role of <sup>68</sup>Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1)'. Together they form a unique fingerprint.

  • Cite this

    Lastoria, S., Marciello, F., Faggiano, A., Aloj, L., Caracò, C., Aurilio, M., D’Ambrosio, L., Di Gennaro, F., Ramundo, V., Camera, L., de Luca, L., Fonti, R., Napolitano, V., & Colao, A. (2016). Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine. https://doi.org/10.1007/s12020-015-0702-y